Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Stock Short Interest Declines 46.6%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large decline in short interest in September. As of September 30th, there was short interest totaling 143,564 shares, a decline of 46.6% from the September 15th total of 268,742 shares. Based on an average daily volume of 239,833 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xtant Medical stock. AWM Investment Company Inc. purchased a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,976,910 shares of the medical device company’s stock, valued at approximately $2,516,000. AWM Investment Company Inc. owned approximately 4.26% of Xtant Medical as of its most recent SEC filing. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Loop Capital set a $1.00 price objective on shares of Xtant Medical in a report on Wednesday, September 2nd. Two analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $1.00.

Xtant Medical Price Performance

NYSEAMERICAN:XTNT traded down $0.00 during trading hours on Wednesday, reaching $0.32. 28,906 shares of the company were exchanged, compared to its average volume of 646,391. The company has a market capitalization of $44.89 million, a P/E ratio of -4.00 and a beta of -0.20. Xtant Medical has a 1-year low of $0.27 and a 1-year high of $0.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.16 and a quick ratio of 1.05. The business has a 50 day moving average of $0.35 and a 200 day moving average of $0.43.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.05). The company had revenue of $23.03 million during the quarter, compared to analyst estimates of $24.88 million. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc is a medical technology company focused on developing, manufacturing and distributing products used in orthopedic and spinal procedures. Its portfolio is designed to support bone growth, spinal fusion and the repair or reconstruction of musculoskeletal structures.

The company offers a range of biologic products, including human tissue allografts, demineralized bone matrix and other bone-graft substitutes. It also provides implantable devices and surgical instruments for spine and orthopedic applications, including products used in interbody fusion and spinal fixation procedures.

Xtant Medical is headquartered in Belgrade, Montana, and serves the U.S.